Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   


Term:Anti-N-Methyl-D-Aspartate Receptor Encephalitis
go back to main search page
Accession:DOID:9003034 term browser browse the term
Definition:Disorder characterized by symptoms of CATATONIA; HYPOVENTILATION; DYSKINESIAS; ENCEPHALITIS; and SEIZURES followed by a reduced CONSCIOUSNESS. It is often followed by a viral-like prodrome. Many cases are self-limiting and respond well to IMMUNOMODULATORY THERAPIES against the NMDA RECEPTORS antibodies.
Synonyms:exact_synonym: Anti NMDA Receptor Encephalitis;   Anti NMDAR Encephalitis;   Anti-N-Methyl-D-Aspartate Receptor Encephalitides;   Anti-NMDA Receptor Encephalitides;   Anti-NMDAR Encephalitides;   Non paraneoplastic Anti N Methyl D Aspartate Receptor Encephalitis;   Non paraneoplastic Anti NMDA Receptor Encephalitis;   Non paraneoplastic Anti NMDAR Encephalitis;   Non-paraneoplastic Anti-NMDAR Encephalitides;   Paraneoplastic Anti N Methyl D Aspartate Receptor Encephalitis;   Paraneoplastic Anti NMDA Receptor Encephalitis;   Paraneoplastic Anti NMDAR Encephalitis;   Paraneoplastic Anti-NMDAR Encephalitides
 primary_id: MESH:D060426;   RDO:0010036
For additional species annotation, visit the Alliance of Genome Resources.

show annotations for term's descendants       view all columns           Sort by:

Term paths to the root
Path 1
Term Annotations click to browse term
  disease 15619
    syndrome 5154
      Paraneoplastic Syndromes 21
        Paraneoplastic Syndromes, Nervous System 16
          Anti-N-Methyl-D-Aspartate Receptor Encephalitis 0
Path 2
Term Annotations click to browse term
  disease 15619
    disease of anatomical entity 14948
      Immune & Inflammatory Diseases 3092
        immune system disease 2518
          Autoimmune Diseases 1478
            autoimmune hypersensitivity disease 1193
              autoimmune disease of the nervous system 404
                Anti-N-Methyl-D-Aspartate Receptor Encephalitis 0
paths to the root


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.